Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
1055(c) 1041.5(c) 1074.5(c) 1073(c) 1088(c) Last
192 016 192 009 229 459 152 208 151 038 Volume
+1.74% -1.28% +3.17% -0.14% +1.40% Change
More quotes
Financials ( DKK)
Sales 2017 2 285 M
EBIT 2017 1 239 M
Net income 2017 1 018 M
Finance 2017 4 663 M
Yield 2017 -
Sales 2018 3 067 M
EBIT 2018 1 591 M
Net income 2018 1 567 M
Finance 2018 6 086 M
Yield 2018 0,01%
P/E ratio 2017 64,75
P/E ratio 2018 44,07
EV / Sales2017 27,1x
EV / Sales2018 19,7x
Capitalization 66 570 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Lisa N. Drakeman and Jan G. 
Sector
Biotechnology & Medical Research
Calendar
02/21 | 05:00pmEarnings Release
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
02/16GENMAB A/S : annual earnings release
02/08MORPHOSYS : Patent Application Titled "Method for the Treatment of Multiple Myel..
AQ
01/25Genmab Announces 2017 Net Sales Figures for DARZALEX
AQ
01/24GENESIS HEALTHCARE : Genmab - U.S. FDA Grants Priority Review for Daratumumab in..
AQ
01/23GENMAB : Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
AQ
01/23GENMAB : Announces Novartis Intention to Transition Arzerra (ofatumumab) from Co..
AQ
01/22JOHNSON & JOHNSON : FDA grants Darzalex Priority Review for first-line MM
AQ
01/22GENMAB : Announces Novartis' Intention to Transition Arzerra® (ofatumumab) from ..
PU
01/22Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab..
GL
01/19GENMAB : U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple ..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/07Jefferies Group Lowers Genmab As Q4 2017 Earnings Estimates to $1.76 EPS (Pre.. 
01/23$GMXAY: Genmab A/S: Darzalex sales (receives royalties from JNJ) +117% in 201.. 
01/23#J&J results top estimates - but Darzalex sales disappoint #Genmab invest..
1
01/22Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from.. 
01/22Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) fr.. 
More tweets
Qtime:35
News from SeekingAlpha
01/263 THINGS IN BIOTECH YOU SHOULD LEARN : January 25, 2018 
01/233 THINGS IN BIOTECH YOU SHOULD LEARN : January 22, 2018 
01/22Novartis to transition availability of Arzerra for CLL to compassionate use e.. 
2017YOUR DAILY PHARMA SCOOP : Valeant's B+L In India, TXMD's NDA Resubmission, Melin.. 
2017Genmab earns $20M milestone from Janssen on daratumumab advancement 
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | GEN | DK0010272202 | 4-Traders
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 421  DKK
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Burton Gordon Malkiel Independent Director
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB4.28%11 055
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
JUNO THERAPEUTICS INC87.75%9 798